CorMedix (CRMD) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CorMedix (CRMD) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 34.4% versus a loss of 37.2%. Over five years, CRMD leads with a +47.1% price change compared with -79.1% for PHAT. CorMedix is the larger company by market cap ($564.7 million vs $552.6 million), about 1.0 times the size.
On valuation, Phathom Pharmaceuticals trades at a lower forward P/E (6.3x vs 20.7x for CorMedix).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | PHAT |
|---|---|---|
| Share price | $7.25 | $6.83 |
| Market cap | $564.71M | $552.55M |
| 1-day change | -0.48% | +0.29% |
| YTD return | -37.40% | -58.95% |
| 1-year return | -34.36% | -37.18% |
| 5-year return | +47.07% | -79.05% |
| P/E ratio (TTM) | 3.53 | — |
| Forward P/E | 20.70 | 6.34 |
| EPS (TTM) | $2.05 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.02 | $18.31 |
| 52-week low | $6.13 | $6.52 |
| Distance from 52-week high | -44.35% | -62.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.59% | +199.41% |
| Average volume | 1.06M | 1.40M |
| Shares outstanding | 77.94M | 80.90M |
| Employees | 191 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
CRMD vs PHAT FAQ
Which is bigger, CorMedix or Phathom Pharmaceuticals?
CorMedix (CRMD) is larger, with a market capitalization of $564.71M compared with $552.55M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, CRMD or PHAT?
CRMD returned -34.36% over the past 12 months, compared with -37.18% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.